SRZN
NASDAQSurrozen Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks43+150%
2026-03-012026-08-23
Mix1190d
- Insider5(45%)
- Other3(27%)
- SEC Filings2(18%)
- Analyst1(9%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on Surrozen with a new price targetWilliam Blair initiated coverage of Surrozen with a rating of Outperform and set a new price target of $51.00
- SECSEC Form 25-NSE filed by Surrozen Inc.25-NSE - Surrozen, Inc./DE (0001824893) (Subject)
- SECSEC Form 10-Q filed by Surrozen Inc.10-Q - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen Reports Second Quarter 2026 Financial Results and Provides Business UpdatePlanned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the secon
- INSIDERLarge owner Tcg Crossover Gp Ii, Llc sold $6,906,250 worth of shares (325,000 units at $21.25) (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- PRSurrozen to Present at Upcoming Healthcare Investor ConferenceSOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026Fireside Chat at 10:00 AM Pacific Time/1:00 PM Eastern Time Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surr
- INSIDERChief Financial Officer Maleki Andrew Pedrum was granted 607 shares (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERExec. Vice President, Research Li Yang was granted 1,666 shares, increasing direct ownership by 10% to 18,882 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Operating Officer Williams Charles O was granted 1,666 shares, increasing direct ownership by 10% to 18,237 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERChief Executive Officer Parker Craig C was granted 1,622 shares, increasing direct ownership by 10% to 18,175 units (SEC Form 4)4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Kutzkey Tim4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Surrozen Inc.SCHEDULE 13D/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)
- INSIDERSEC Form 4 filed by Director Rothenberg Mace4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Woodhouse David J4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Haak-Frendscho Mary4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Chai Christopher Y4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Bjerkholt Eric4 - Surrozen, Inc./DE (0001824893) (Issuer)
- INSIDERSEC Form 4 filed by Director Berkenblit Anna4 - Surrozen, Inc./DE (0001824893) (Issuer)
- SECSurrozen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Surrozen, Inc./DE (0001824893) (Filer)
- PRSurrozen to Present at Upcoming Healthcare Investor ConferenceSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 Fireside Chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.s
- SECSEC Form 10-Q filed by Surrozen Inc.10-Q - Surrozen, Inc./DE (0001824893) (Filer)
- SECSurrozen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Surrozen, Inc./DE (0001824893) (Filer)
SRZN FAQ
6 questionsWhat does Surrozen Inc. do?
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific...Where does SRZN stock trade?
Surrozen Inc. (SRZN) is listed on NASDAQ.What sector and industry is SRZN in?
Surrozen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about SRZN?
Surrozen Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-08-20. Recent price targets range from $1100.00 to $4500.00.What companies are similar to SRZN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SRZN side-by-side with any of them on Quantisnow.How can I track SRZN on Quantisnow?
Quantisnow aggregates Surrozen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRZN to receive live email and push alerts on every new disclosure.